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Abstract Expression of certain mammalian protein kinase C 
(PKC) isoforms inhibits the proliferation of Schizosaccharo-
myces pombe (Goode et al., Mol. Biol. Cell 5 (1994) 907-920). 
We have taken advantage of this fact to determine the in vivo 
isoform preference of a number of PKC inhibitors, using a 
microtitre plate assay which allows rapid screening. This in vivo 
model has revealed previously unreported preferences; calphostin 
C is a more efficient inhibitor of the novel PKC5 than 
chelerythrine chloride whereas the efficiencies are reversed for 
inhibition of the classical PKCy. We have also shown that the 
anti-leukaemic agent bryostatin 1 inhibits or activates in vivo in 
an isoform-specific manner. 
© 1997 Federation of European Biochemical Societies. 
Key words: Protein kinase C; Isoform; Inhibitor; Activator; 
Schizosaccharomyces pombe 
1. Introduction 
Protein kinase C (PKC) is a major transducer of signals in 
response to the generation of diacylglycerol (reviewed in [1,2]). 
As the receptor for the tumour-promoting phorbol esters [3] it 
has excited much interest as a potential target for tumour 
therapy and both activators and inhibitors of PKC have en-
tered the clinical trial stage [4,5]. In order to investigate the 
role of PKC in signal transduction, extensive use is made of 
pharmacological agents as both activators and inhibitors of 
PKC activity. If a response can be elicited by treatment of 
cells with an activator such as 12-O-tetradecanoylphorbol 13-
acetate (TPA) then PKC activation is assumed to be sufficient 
for signal transduction. If a response is blocked by an inhib-
itor of PKC then PKC activity is necessary, though not nec-
essarily sufficient, for the response. In addition, prolonged 
treatment of cells with TPA leads to a loss of PKC in a 
process known as down-regulation in which activated PKC 
is degraded. Such cells are rendered deficient in PKC signal-
ling. 
Although PKC was originally described as a single activity, 
cloning has revealed the existence of a complex family of 
enzymes with at least ten genes encoded in the human genome 
and evidence for alterative splice forms to further increase the 
potential number of proteins involved (reviewed in [1,2]). 
These isoforms can be subdivided on the basis of sequence 
homology and biochemical properties into three families: con-
ventional, novel and atypical PKCs. Where investigated, cells 
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appear to express a range of isoforms in varying concentra-
tions (e.g. [6,7]). The expression of multiple isoforms is sup-
portive of isoform-specific functions. There is increasing evi-
dence, mainly from overexpression studies, that different 
isoforms do carry out unique functions in the cell [8-10]. 
Immunohistochemical analysis has also revealed distinct iso-
form-specific compartmentalisation consistent with this theory 
[11,12]. Thus a full understanding of a signalling pathway 
must include definition of which isoform of PKC is involved 
and knowledge of the isoform specificity of activators and 
inhibitors of PKC is vital in the interpretation of experiments 
involving their use. The development of compounds which 
modulate the activity of an individual isoform will allow ma-
nipulation of a single response with minimal effect on other 
PKC-dependent pathways. 
The isoform specificity of a small number of PKC inhibitors 
has been determined using purified PKCs [13,14]. The purifi-
cation of individual PKC isoforms from tissue or cell sources 
is not trivial as most express a range of isoforms with similar 
Chromatographie properties. PKCs expressed in bacteria have 
no activity [15,16] and so cannot be used for such analysis, so 
the most efficient method of isolating a single isoform for 
biochemical studies is expression using a baculovirus expres-
sion system with subsequent purification [17]. This is labour-
intensive and the endogenous PKCs of Sf9 insect cells have 
not been characterised so there is a risk of contamination of 
expressed protein with an insect PKC. Furthermore, the in 
vitro behaviour of PKCs may not fully represent their behav-
iour in the whole cell where there may be compartmentalisa-
tion effects as well as metabolism of compounds and compe-
tition with other cellular components. Thus an in vivo assay 
to determine the effect of modulators of PKC activity will 
provide a more accurate assessment of the consequences for 
the whole cell. 
We have devised a rapid in vivo assay for identifying PKC 
activators and inhibitors which allows determination of their 
isoform specificity. Expression of individual isoforms of mam-
malian PKCs in the fission yeast Schizosaccharomyces pombe 
causes a TPA-dependent growth inhibition which depends on 
the activity of the expressed PKC [18]. We report here that 
this effect can be reversed by the addition of known inhibitors 
of PKC activity. We have devised a microtitre assay which 
can be used as a rapid screening system to determine if phar-
macological agents act as inhibitors of individual PKC iso-
forms. This system has been used to determine the relative 
efficacy on individual PKC isoforms of some inhibitors which 
are currently widely in use. The relative efficiency of growth 
restoration varies between isoforms suggesting that treatment 
of intact cells with these inhibitors will not have an equal 
effect on inhibiting all isoforms of PKC present. 
This assay can also be used to identify and evaluate the 
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Fig. 1. Growth phenotype and effect of TPA on S. pombe strains expressing PKC. S. pombe strains expressing either the vector control (A), 
PKCy (B) or PKC5 (C) were precultured in minimal selective medium without thiamine to allow induction of PKC expression until an OD595 
of 0.4-0.6 was reached. The strains were then diluted to an OD595 of 0.03 (5X 105 cells/ml) in minimal selective media with no additions, 1 μΜ 
thiamine or 200 ng/ml TPA as indicated. The cell density was determined after the indicated intervals of culture at 30°C. Results are the mean 
of triplicate samples ± standard deviation and are from one experiment, representative of 10. The control, PKCy and PKC8 transformants 
reached saturation densities (OD) of 0.87, 0.69 and 0.89 respectively. 
isoform specificity of PKC activators. PKC activators also 
have potential as anticancer agents as, for example, they cause 
the terminal differentiation of a number of haematopoietic cell 
types. Highly specific agents which activate only the required 
isoforms would be of interest for use in such cases. We have 
examined the effects of the mixed PKC agonist/antagonist 
bryostatin 1 on two isoforms of PKC and report opposing 
effects on two isoforms. 
2. Materials and methods 
All PKC inhibitors were purchased from Calbiochem; TPA and 
amino acids were purchased from Sigma. The PKC activator bryosta-
tin was a kind donation from G. Radda, Oxford. The monoclonal 
36G9 PKCy antibody [19] was obtained from Peter Parker (ICRF, 
London). All other antibodies used and the enhanced chemilumines-
cence (ECL) detection system were obtained from Amersham Interna-
tional. 
2.1. Growth of S. pombe 
Mammalian PKCs were expressed in S. pombe strain h-, ade6-704, 
leul-32, ura4-A18, under the control of the thiamine-repressible pro-
moter in the pREP series of vectors [18]. Cells were transfected with 
either empty vector or the PKC expression vector [18]. The resulting 
transformants were tested for the ability of TPA to inhibit growth in 
the absence of thiamine by streaking on fully supplemented Edin-
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Fig. 2. Restoration of TPA-induced growth inhibition by bisindolylmaleimide. Cell growth was assayed as described in the legend to Fig. 1, 
with no additions, 200 ng/ml TPA or the combination of 200 ng/ml TPA with 3 μΜ bisindolylmaleimide (Bis). The Γ50 value (time taken to 
reach 50% of saturation density) for each condition is expressed in the associated tables for vector control (A), PKCy (B) or PKC8 (C). Results 
are the mean of triplicate samples ± standard deviation from one experiment, representative of 10. The control, PKCy and PKC8 transformants 
reached saturation densities (OD) of 0.59, 0.92 and 0.84 respectively. 
burgh minimal medium (EMM) plates [20] containing 100 ng/ml TPA. 
Single colonies were picked and grown in culture overnight in the 
presence of thiamine. Cells were then washed three times to remove 
the thiamine and cultured overnight in the absence of thiamine. Cells 
(OD595 0.4-0.6) were diluted into 150 μΐ (final volume) in triplicate in 
a 96-well microtitre plate (flat bottom wells) to an OD595 of 0.03 in 
EMM (supplemented with 2% w/v glucose, adenine (150 mg/1), uracil 
(150 mg/1) or leucine (150 mg/1)), and containing thiamine (1 μΜ), 
TPA (200 ng/ml) or inhibitors as indicated. For those inhibitors dis-
solved in DMSO control cells with the appropriate volume of DMSO 
confirmed that the solvent had no effect on cell growth. The cells were 
incubated with slow shaking at 30°C in a sealed box containing moist 
tissues. The outer wells of the plate were not used as these sometimes 
dried out on prolonged incubation at 30°C. The growth was moni-
tored by determining the OD595 at various time intervals using a plate 
reader (Molecular Devices, Raleigh Court, Crawley). 
The effect of each inhibitor was assessed by comparing the time 
taken for the cells incubated in the presence of TPA with or without 
inhibitors to reach 50% of the final saturation density of cells incu-
bated without additives (T50). Final saturation density used to calcu-
late the r50 value for each experiment is indicated in the figure 
legends. The relationship between the Γ50 value and the growth profile 
of S. pombe strains is outlined in Fig. 2. Γ50 values were obtained for 
each experiment by visual inspection of the data. The densities of each 
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Table 1 
The effects of Gö 6976 and rottlerin on 
Culture conditions 
No additions 
TPA (200 ng/ml) 
TPA+rottlerin (15 μΜ) 
TPA+Gö 6976 (10 μΜ) 
growth of S. pombe PKC transformante 
7-50 (h) 
PKCy 
30±1 
60 ±5 
59±6 
43 ±1 
PKC5 
29 ±1 
75 ±1 
63 ±3 
72 ±8 
Vector 
31 ±1 
30±1 
31 ± 1 
32 ±1 
S. pombe PKC transformants were incubated without additions, in the presence of TPA or in the presence of TPA and either rottlerin or Gö 6976 
at the indicated concentrations. OD595 readings were taken at 12 h intervals and the Γ50 value (h) for each condition was determined. The results 
shown are the means of triplicate samples from a single experiment, representative of four. All the values in this table were obtained in a single 
experiment. 
individual culture well were plotted independently and three TBO val-
ues determined for each condition. These were then averaged to de-
termine the mean Γ50 with a standard deviation. 
2.2. Western blot analysis 
Denatured protein extracts were made from equivalent numbers of 
cells as described [20]. Protein extracts were subjected to 10% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western blotted as described elsewhere [21]. The PKCy 36G9 mono-
clonal antibody was followed by a sheep anti-mouse horse radish 
peroxidase-conjugated antibody and the ECL detection system. 
3. Results 
S. pombe cells expressing either a conventional isoform of 
PKC (PKCy) or a novel isoform (PKCö) under a thiamine-
repressible promoter were examined for their ability to show 
TPA-dependent growth inhibition when grown in microtitre 
plates. Treatment of cells expressing either isoform with TPA 
led to growth inhibition compared with the cells not express-
ing PKC (cultured in the presence of thiamine) ([18] and Fig. 
1). The strains expressing PKC show some growth inhibition 
in the absence of TPA, presumably due to background acti-
vation of the expressed PKC. Within an experiment the satu-
ration density for a particular cell strain was always identical, 
irrespective of the presence of thiamine, TPA or inhibitor -
only the time taken to reach this density varied. Differences in 
the saturation density are seen between experiments due to 
slight differences in growth conditions. The time at which 
the TPA-dependent inhibition was lost varied between iso-
forms, presumably dependent on the rate of down-regulation 
of the PKC from the S. pombe cells. As TPA causes down-
regulation and loss of the PKC from the cell, the growth 
returned gradually to normal rates ([18] and Fig. 1). 
3.1. The effects of PKC inhibitors 
The inhibition of growth induced by TPA in both PKCy 
and PKC5 transformants could be reversed by the inclusion of 
known inhibitors of PKC. Fig. 2 illustrates the growth curves 
for the PKC5- and PKCy-expressing cells cultured in the pres-
ence of TPA and the PKC inhibitor bisindolylmaleimide 
(GF109203X). A reversal of growth inhibition is apparent 
while growth of control cells transfected with vector alone 
was not significantly altered. At high concentrations the in-
hibitors did have effects on control cells alone so for all in-
hibitors the concentrations were chosen to be below this 
threshold level. We have used the time taken to reach 50% 
of the 750, of cells alone, as a measure of the initial growth 
rate in strains under various conditions as this includes differ-
ences in lag time as well as in doubling time and we have 
found it to give an accurate reflection of the efficacy of the 
inhibitors (Fig. 2 and data not shown). The absolute values of 
750 varied between experiments, presumably due to slight dif-
ferences in the initial plating density. However all the trends 
reported here were reproducible. The ability of PKC inhibi-
tors to reverse the growth defect in these strains, therefore, 
provides a rapid screening method for testing new compounds 
for their ability to inhibit individual isoforms of PKC. In 
PKCy expressing cells treated with TPA the inclusion of bis-
indolylmaleimide (3 μΜ) reduced the T50 to 34 ± 1 h from 
53 ± 5 h. In PKC5 transformants bisindolylmaleimide induced 
a 41 h decrease in T50. 
The ability of this assay to distinguish isoform-specific ef-
fects was confirmed by comparing the effect of the ATP ana-
logue Gö 6976 on the growth of cells expressing PKC6 and 
PKCy. This compound is reportedly specific for the conven-
tional PKCs with IC50 of 2-6 nM [13]. This was reflected in 
the reversal of growth inhibition at a given concentration of 
Gö 6976 (10 μΜ) having no effect on the growth time for 
PKC5 expressing cells while inducing a 17 h decrease in T5o 
in PKCy-expressing cells (Table 1). Conversely rottlerin has 
been reported to be specific for PKC6 [23] and this specificity 
Table 2 
The effects of calphostin, chelerythrine and D-eryiArosphingosine on the growth of S. pombe PKC transformants 
Culture conditions Γ50 (h) 
PKCy PKC8 Vector 
No additions 
TPA (200 ng/ml) 
TPA+calphostin (125 nM) 
TPA+chelerythrine (26 μΜ) 
TPA+D-eryíArosphingosine (1 μΜ) 
36 ±1 
76±2 
64±1 
56 ±1 
55±2 
35 ±1 
115±1 
39±3 
75 ±7 
36±3 
37 ±1 
37 ±1 
36 ±1 
36 ±1 
35 ±1 
S. pombe PKC transformants were incubated without additions, in the presence of TPA or in the presence of TPA and either calphostin, 
chelerythrine or D-eryiArosphingosine at the indicated concentrations. OD595 readings were taken at 12 h intervals and the Γ50 value (h) for 
each condition was determined. The results shown are the means of triplicate samples from a single experiment, representative of four. All the 
values in this table were obtained in a single experiment. 
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Table 3 
A comparison 
Inhibitor 
of the in vitro IC50 values of PKC inhibitors with the 
IC50 
Mix Y 
in vivo percentage 
δ 
inhibition of PKC-induced growth effect 
% Reversal 
Y δ 
Rottlerin 
Gö 6976 
Calphostin 
Chelerythrine 
D-^fjiArasphingosine 
Bis 
NA 
NA 
50 nM 
660 nM 
600 nM 
10 nM 
40 μΜ 
2-6 nM 
NA 
NA 
NA 
20 nM 
3-6 
* 
NA 
NA 
NA 
NA 
μΜ 3 
37 
30 
50 
53 
58 
57 
7 
95 
50 
99 
45 
The table outlines a comparison between the published data on in vitro IC50 values [13,22,23] for each inhibitor examined and the results obtained 
with the in vivo assay described in this paper. The IC50 values presented are for either a mixture of PKC isoforms (Mix), or individual isoforms 
where data are available. NA indicates IC50 values not available, * indicates not detectable, Bis is bisindolylmaleimide. The in vivo assay results are 
presented as % reversal of the growth defect and are calculated as follows: 
7,5ο(ΤΡΑ)-Γ5ο(ΤΡΑ + inhibitor) 
Γ5ο(ΤΡΑ)-Γ5ο(ηο additions) 
X100. 
The % reversal values were calculated from the data in Tables 1 and 2 and Fig. 2, and hence the concentration of inhibitors examined and the final 
saturation densities are as outlined in the relevant legends. 
was readily apparent using our assay system. Rottlerin in-
duced a 12 h decrease of T50 in cells expressing PKC5 whereas 
an insignificant difference in growth rate was observed in con-
trol cells and those expressing PKCy. 
Having determined that the assay system was capable of 
distinguishing the isoform specificity of PKC inhibitors, the 
relative ability of some widely used PKC inhibitors to restore 
growth of cells expressing individual PKC isoforms was de-
termined (Table 2). One classical isoform (PKCy) and one 
novel isoform (PKC5) were investigated as representatives of 
the subfamilies of PKC. The PKC inhibitors tested included 
one targeting the ATP binding site (chelerythrine chloride) 
and others that target regulatory sequences (calphostin C, D-
ery?/;rosphmgosine) [22]. The isoform specificity of these in-
hibitors has not been previously reported. The results indi-
cated that significant differences occur. PKCy was relatively 
insensitive to calphostin C (125 nM) whereas chelerythrine 
chloride (26 μΜ) inhibited PKCy to a greater extent. In con-
trast cells expressing PKC6 showed reversed sensitivity with 
significant inhibition by this same concentration of calphostin 
C, whereas the cells were relatively refractory to 26 μΜ chel-
erythrine chloride. D-isryiArosphmgosine had an effect similar 
to chelerythrine chloride in PKCy transformante but was 
much more effective than chelerythrine in PKC6 expressing 
cells. Thus previously unreported isoform preferences of these 
PKC inhibitors in the intact cell have been revealed. Table 3 
outlines a comparison of the results obtained in this study 
with the reported IC50 values for each inhibitor. This table 
further indicates that reported in vitro isoform specificities for 
the PKC inhibitors examined have been confirmed using our 
in vivo system. 
3.2. The effects of a PKC activator 
In addition to examining the effects of PKC inhibitors, this 
assay system can also be used to look at the isoform specific-
ity of PKC activators. We have chosen to look at the effect of 
bryostatin as this compound will activate PKCs in vitro but 
has significantly different effects to phorbol esters when added 
to whole cells. Bryostatins are natural products that have anti-
leukaemic activity [24] and are in use in clinical trials although 
the mechanism of action is not well established. We compared 
the effects of bryostatin 1 with TPA on the growth of the 
PKCy and PKC8 transformants (Fig. 3). The results suggest 
that bryostatin 1 activates PKC5, as indicated by a decrease in 
growth rate compared to PKC6 transformants incubated in 
the absence of PKC activators (Fig. 3C). A similar effect was 
anticipated for cells expressing PKCy but in fact the growth 
rate of PKCy transformants was increased by the presence of 
bryostatin (Fig. 3B); it appears to antagonise PKCy activity. 
Several explanations are possible. Rapid loss of immunoreac-
tive PKC in response to bryostatin treatment has been re-
ported in a variety of cell lines and used to explain differences 
between cellular responses to bryostatin and phorbol esters 
[25-27]. Thus it is possible that bryostatin induced extremely 
rapid down-regulation of PKCy in S. pombe leading to a rapid 
relief of PKCy-induced growth inhibition and a subsequent 
return to normal growth rates. However, in our system 
PKCy expression levels were comparable to untreated cells 
after culture with bryostatin for 24 h, whereas this isoform 
was almost completely down-regulated in TPA treated cells 
(Fig. 4A). Stripping and re-probing the same Western blot 
with an antibody against a protein whose expression levels 
are not expected to change was used to control for the levels 
of protein loading (Fig. 4B). These results suggest that bryo-
statin does not activate PKCy but may, in fact, act as an 
inhibitor of activity, reversing the small degree of growth in-
hibition seen in the absence of TPA treatment. Thus in our in 
vivo experimental system bryostatin exhibits a distinct isoform 
specificity, activating PKC6 while leading to inhibition of 
PKCy. 
4. Discussion 
We have developed a rapid assay for determining the ability 
of reagents to inhibit individual isoforms of PKC. This meth-
od is applicable to screening unknown compounds firstly for 
their ability to inhibit PKC and secondly to demonstrate spe-
cific inhibition of individual isoforms. The assay depends on 
the TPA-dependent growth inhibition exhibited by S. pombe 
cells expressing individual isoforms of PKC. As this growth 
inhibition depends on PKC activity [18] we have shown that 
the inclusion of inhibitors of PKC can reverse this growth 
defect. Reversal of growth inhibition is also apparent in the 
absence of TPA but the inclusion of TPA, by increasing the 
growth inhibition, greatly increases the sensitivity of the assay 
and allows small differences in inhibitor efficiency to be deter-
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Fig. 3. The isoform-specific effects of the PKC activator bryostatin 1. Cell growth was assayed as described in the legend to Fig. 1, in the pres-
ence of no additions, 200 ng/ml TPA or 200 ng/ml bryostatin as indicated. The cell density was determined after the indicated intervals of cul-
ture at 30°C. Results are the mean of triplicate samples ± standard deviation, from one experiment, representative of 3. The control, PKCy and 
PKC8 transformants reached saturation densities (OD) of 0.75, 0.57 and 0.60 respectively. 
mined (unpublished observations). TPA has no effect on con-
trol cell growth (Figs. 1-3) and so is included only to activate 
all the expressed mammalian PKC. It is not clear whether it is 
the activation of the PKC itself or its subsequent downregu-
lation which is causing the growth defect. However, as all are 
dependent on PKC activity [18] this does not effect the val-
idity of the assay and as both events will be occurring in 
response to PKC activators in mammalian cells, this in vivo 
assay is a better model for the effect of inhibitors in the intact 
cell than an in vitro determination of IC50. Both isoforms 
tested here do downregulate on prolonged TPA treatment 
(Fig. 4 and [18]) with similar efficiency. We have used the 
time taken to reach 50% of the T50 as a convenient measure 
of the growth rate of cells under varying conditions. Compar-
ison of the Trl0 values allows the efficacy of inhibitors to be 
assessed on a single PKC isoform in an intact cell. This may 
be significantly different from the effect in an in vitro kinase 
assay due to the influence of other cellular components. The 
use of a microtitre plate assay system allows rapid screening 
of a large number of compounds at varying concentrations. 
We have used the assay to determine the relative efficiency 
of inhibition of a range of widely used PKC inhibitors on 
representative members of the conventional and novel PKC 
subfamilies. Although this method cannot be used to deter-
mine an IC50 as there is no way of judging the concentration 
of inhibitor present in the cell, it can be used to determine the 
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Fig. 4. Expression of PKCy in cells treated with bryostatin 1 and 
TPA. A: Denatured extracts collected from vector control and 
PKCy-expressing cells cultured for 24 h with no additives (N), 200 
ng/ml TPA (P) or 200 ng/ml bryostatin (B) were analysed by West-
ern blot using the 36G9 PKCy monoclonal antibody. The position 
of PKGy is indicated by the arrow. The smaller bands are presumed 
to be degradation products of full-length PKCy and have been re-
ported in previous use of this system [18]. B: The Western blot was 
stripped and reprobed with polyclonal anti-ERK (Santa Cruz K-23) 
antibody to control for protein loading. 
relative efficiency of individual isoform inhibition. The use of 
an in vivo assay means that the effect of these compounds can 
be determined in a cell background and is more likely to 
reflect their true activity in the cell rather than an in vitro 
system using purified components. The ability of the assay 
to detect isoform specificity of inhibitors was confirmed by 
testing the ability of compounds known to show preference 
for certain isoforms to reverse the growth inhibition of strains 
expressing individual isoforms. The P K C inhibitor G ö 6976 
with specificity for conventional isoforms [13] induced a re-
versal in growth inhibition only in PKCy-expressing cells. 
Conversely rottlerin, which has been reported to be specific 
for P K C 5 [23], induced a reversal of TPA-induced growth 
inhibition only in cells expressing PKC6. 
The isoform specificity of many widely used P K C inhibitors 
is not known due to difficulties in obtaining purified prepara-
tions of a single isoform. Those which have been reported rely 
on an in vitro assay rather than quantifying their effects in the 
cell where many other components may influence the effi-
ciency of P K C inhibition. We have tested some of the com-
monly used inhibitors in our assay system and are able to 
detect isoform specificity. For example we found that calphos-
tin C showed a greater efficiency of inhibition of P K C 5 while 
chelerythrine chloride showed a preference for PKCy. The 
differences in relative efficiencies of these compounds has 
wide implications for their use as P K C inhibitors on cells 
that are expressing a range of P K C isoforms. Treatment 
with limiting concentrations of inhibitors will preferentially 
inhibit one isoform and perhaps one pathway rather than 
all PKC-dependent events. Obviously the effects within a 
cell will also depend upon the relative concentrations of 
P K C isoforms, but the specificities demonstrated here will 
play an important role in developing strategies to modulate 
cell function using these inhibitors. 
Apar t from the interest in P K C inhibitors there is a need to 
establish an assay for P K C isoform-specific activators. Such 
compounds would be of use experimentally as well as thera-
peutically. We have also shown that this assay can be used to 
determine the ability of compounds to activate individual iso-
forms of P K C . Bryostatin is widely used to modulate P K C 
function and bryostatin 1 has been used in phase 1 clinical 
trials [5] but without a full understanding of its mechanism of 
action. Treatment of cells with bryostatin, however, does not 
mimic treatment with the other major P K C activators (phor-
bol esters) and several studies have indicated that bryostatins 
have mixed activator/inhibitor effects on P K C activity in a 
variety of cell types [28-30] which may reflect an isoform-
specific effect. However, in vitro studies using purified PKCs 
have not revealed any isoform-specific differences in bryosta-
tin interaction [31,32]. We report here that this compound will 
activate P K C 5 but inhibits P K C y activity when expressed in 
S. pombe cells. This finding will not only help explain the 
mechanism of action of bryostatin but may also lead to a 
clearer understanding of the role of individual P K C isoforms 
in the process of carcinogenesis. 
This novel model has been shown to be valid for the iden-
tification of P K C isoform-specific activators and inhibitors. It 
can be extended to include all the isoforms of P K C which give 
a growth phenotype in this system and can, therefore, give a 
great deal of information of general use. 
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